IKT — Inhibikase Therapeutics Share News
0.000.00%
Last trade - 00:00Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics files for mixed shelf of up to $300 mln
Inhibikase Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025
Brief: Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO
Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
Brief: Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability